ARTICLE | Clinical News
Pyridoxamine: Phase III ongoing
February 1, 2016 8:00 AM UTC
NephroGenex said an independent DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III PYR-311 trial evaluating 300 mg oral Pyridorin twice daily until ESRD or ...